EQ-5D-5L Health-State Values for the Mexican Population. by Gutierrez-Delgado, C et al.
Vol.:(0123456789)
Applied Health Economics and Health Policy 
https://doi.org/10.1007/s40258-021-00658-0
ORIGINAL RESEARCH ARTICLE
EQ‑5D‑5L Health‑State Values for the Mexican Population
Cristina Gutierrez‑Delgado1,2 · Rosa‑María Galindo‑Suárez3,4 · Cesar Cruz‑Santiago3,4 · Koonal Shah5 · 
Manny Papadimitropoulos6,7 · Yan Feng8 · Bernarda Zamora9 · Nancy Devlin9,10
Accepted: 14 March 2021 
© The Author(s) 2021
Abstract
Objective To generate a value set for the Mexican adult general population to support and facilitate the inclusion of quality-
adjusted life years (QALYs) into the health technology assessment process of the Mexican healthcare authorities.
Methods A representative sample of the Mexican adult population stratified by age, sex and socio-economic status was used. 
Following version 2.0 of the EuroQol EQ-5D-5L valuation protocol, trained interviewers guided participants in completing 
composite time trade-off (cTTO) and discrete-choice experiment (DCE) tasks included in the EQ-VT software. Generalized 
least squares, Tobit and Bayesian models were used for cTTO data. The choice of value set model was based on criteria that 
included: theoretical considerations, parsimony, logical ordering of coefficients, and statistical significance.
Results Based on quality control criteria and interviewer judgment, 1000 out of 1032 participants provided useable responses. 
Participants’ demographic characteristics were similar to the 2010 Mexican Population Census and followed the socioeco-
nomic structure defined by the Mexican Association of Marketing Research and Public Opinion Agencies (AMAI). The 
predicted index values in the final cTTO model (a heteroscedastic censored model with Bayesian estimation) ranged from 
− 0.5960 to 1, with 19.7% of all predicted health state scores less than 0 (i.e., worse than dead).
Conclusion This study has generated the first value set representing the stated preferences of the Mexican adult population 
for use in estimating QALYs. The resulting EQ-5D-5L value set is technically robust and will facilitate health economic 
analyses as well as quality-of-life studies.
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Key Points for Decision Makers 
The EQ-5D-5L Mexican value set will facilitate both 
cross-country comparisons and inclusion of Mexican 
participants in international multicenter clinical trials of 
new medical technologies and quality-of-life studies.
The Mexican value set will facilitate the inclusion of 
QALYs into the HTA process that Mexican healthcare 
authorities apply for new medical technologies to be 
financed by public healthcare institutions.
The Mexican value set will allow use of EQ-5D-5L, a 
preference-based health-related quality-of-life measure, 
to quantify patients’ health outcomes in Mexico. These 
data can be used in health economic analysis and con-
tribute to the monitoring of healthcare service quality in 
the Mexican context.
1 Introduction
Mexico, with a population of just over 125 million in 2018 
[1], is considered the second biggest market for medi-
cal technology in Latin America, just behind Brazil [2]. 
Since 2003, the General Health Council (GHC) has posi-
tioned itself as the main health technology assessor (deci-
sion maker) of the public institutions given that it is this 
collegiate body’s sole responsibility to constantly main-
tain and update the Basic Formulary of Medications and 
Healthcare Supplies Catalogue (BFMHSC) [3–7]. This 
document groups, characterizes, and encodes the drugs, 
medical materials, instruments, medical equipment, and 
diagnostics used by the National Health System’s public 
institutions to provide health services to the population. In 
2020 the GHC decided to transform the BFMHSC into the 
National Compendium of Healthcare Supplies (“Compen-
dium”). The Compendium aims to strengthen the evalua-
tion of healthcare, to optimize public resources directed at 
addressing health problems in the country, and to notify and 
update health professionals. The GHC periodically updates 
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the health technology assessment (HTA) processes used to 
determine inclusion in the Compendium.
HTA in Mexico has relied mainly on cost per life-year 
analyses. However, the GHC wishes to extend this to include 
quality of life and quality-adjusted life years (QALYs). To 
include evidence on cost per QALYs gained, it is necessary 
to measure and value health-related quality of life. Several 
generic preference-based measures of health-related quality 
of life exist for this purpose. One of the most widely used, 
internationally, for the purpose of facilitating cost-effective-
ness analysis, is the EQ-5D-5L [8]. The EQ-5D-5L summa-
rizes health in terms of five dimensions (mobility, self-care, 
usual activities, pain/discomfort, anxiety/depression) and 
five levels of problems (no = 1, slight = 2, moderate = 3, 
severe = 4, extreme/unable to = 5). Its use in HTA involves 
collection of EQ-5D-5L data from patients (e.g., in clinical 
trials) and summarizing those data using a “value set.” The 
value sets indicate how good or bad each health state is, on 
a scale anchored at 1 (full health) and 0 (dead), as required 
for the estimation of QALYs. The value sets are generally 
based on the views of a general public sample, obtained 
using stated preference elicitation methods [9].
The GHC is strongly interested in adopting results from 
an internationally well-established methodology for valu-
ing health-related quality of life, suitable for routine use in 
HTA. Hence, the GHC supported a project developed by 
the Economic Analysis Unit (EAU) of the Mexican Min-
istry of Health to estimate the first EQ-5D-5L value set for 
the Mexican population using the EuroQol Group’s interna-
tional EQ-5D-5L valuation protocol and software. Ration-
ales for GHC and EAU selecting the EQ-5D-5L include the 
widespread use of the instrument worldwide in cost-utility 
analysis [10], and its acceptance by key HTA bodies for use 
in evidence submitted to their decision-making processes 
[11–13]. The EQ-5D-5L is also suitable for use in popula-
tion health studies, and in routine outcomes measurement 
in health-care systems (such as the English NHS PROMs 
programme and Swedish National Quality Registers) [14, 
15]. A further rationale for selecting the EQ-5D-5L is the 
availability of an international protocol to support and guide 
the generation of a value set. This protocol has been used to 
generate EQ-5D-5L value sets in over 20 countries to date, 
and its methods and processes for quality control have been 
refined and strengthened to ensure that population prefer-
ences are captured in a robust manner, which is required for 
application in HTA [16].
To address the GHC’s requirements, the main objective of 
this study was to generate a value set for the Mexican adult 
general population to support and facilitate the inclusion 
of QALYs into the HTA process of the Mexican healthcare 
authorities.
2  Methods
2.1  Study Design
A nationally representative sampling of the Mexican adults 
(18 years and older) stratified by sex, age, and socioeco-
nomic level was designed and used. The design followed 
geographical and population frames developed by CONAPO 
[1], the Mexican Office of Statistics and Geography [17], as 
well as the socioeconomic classification of households of 
the Mexican Association of Marketing Research and Public 
Opinion Agencies (AMAI) [18]. To ensure the sample size 
of 1,000 completed interviews recommended by the EQ-
5D-5L valuation protocol, a 15% non-response rate was 
considered (see detailed sampling design in Section 1 of the 
ESM Appendix).
Two methods were used to elicit stated preferences from 
the sample: (a) composite time trade-off (cTTO), compris-
ing “conventional” TTO to obtain values ≥ 0, and a “lead-
time TTO” to obtain values < 0 [19], and (b) discrete-choice 
experiments, involving pairwise choices between health 
states. Face-to-face computer-assisted interviews were 
undertaken with the Mexican general public aged 18 years 
and over. The study design, sampling, and data quality moni-
toring followed the EQ-5D-5L valuation protocol version 
2.0 that has emerged as best practice from previous studies 
[14]. This included a training process for the Mexican study 
team and weekly follow-up meetings with EuroQol Office 
scientists during the data collection phase. It also recom-
mends a minimum sample of 1000 useable respondents [20].
A prior decision was made to base the Mexican value set 
on cTTO data only, as long as the cTTO data were of high 
quality and the resulting value set showed desirable charac-
teristics such as logically ordered parameter estimates. This 
is in line with the approach used in many other countries’ 
value-set studies (e.g., [21–25]). DCE data alone can be used 
to obtain values on a latent scale, but these do not meet the 
conventions of QALY estimation [26]. cTTO and DCE data 
can be combined via hybrid modelling [27], but there is a 
lack of consensus about the merits of this approach, and, 
notably, the new UK value set for EQ-5D-5L now underway 
is based on cTTO only [28]. The design, methods, results, 
and analyses relating to the DCE data are reported in Sec-
tion 2 of the ESM Appendix.
2.2  Valuation Intervention and Methods of Eliciting 
Preferences
The EuroQol Valuation Technology (EQ-VT) software cap-
tured respondents’ preferences regarding EQ-5D-5L health 
states. A sub-set of 86 health states were valued directly 
in the cTTO tasks. From this sub-set, blocks of ten health 
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states were generated, each containing the worst health state 
(55555), one mild state (level 2 in one dimension only), and 
eight states that varied in severity. Further details about the 
experimental design are reported by Oppe and van Hout 
[20]. The software randomly assigned participants to cTTO 
blocks.
2.3  Data Collection and Quality Control Process
Data were collected in the period June–August 2019 by a 
team of 15 interviewers. The interviewers were chosen from 
42 candidates who had been recruited by a public opinion 
agency (De las Heras—Demotecnia). Selection criteria 
included possession of a social science background (sociolo-
gists, social anthropologist, social workers, psychologists, 
historians) and experience in in-depth interviewing. During 
the training process two interviewers opted out for personal 
reasons. Another was discharged during the pilot phase for 
not meeting the required quality standards [29].
2.4  Data Exclusions
Prior to commencing data analysis, the study team agreed 
to exclude two sets of data on quality grounds: (a) cTTO 
data for any respondents who gave the same value for all 
ten health states; and (b) any cTTO observations flagged for 
exclusion by the respondent via the feedback module (a fea-
ture in the EQ-VT that allows respondents to view the rank 
ordering of health states that would be inferred from their 
cTTO responses, and offers them the opportunity to flag any 
health states they feel, on reflection, may have been evaluate 
inappropriately). The former exclusion rule is commonly 
used in value set studies [30]; the latter has regularly been 
used in recent EQ-5D-5L valuation studies following the 
introduction of the feedback module (e.g., [31]).
Interviewer effects were assessed, for example, by com-
paring interviewers’ cTTO value distributions. If the data 
for a given interviewer showed highly unusual patterns or 
suggested protocol non-compliance, then those data were 
excluded on quality grounds. However, such effects were 
assessed throughout the data collection phase. This included 
analysing the interim data on a weekly basis and providing 
regular feedback to interviewers about their performance 
(such as whether they were spending sufficient time explain-
ing the TTO task to respondents), in line with best practice 
[29], thereby minimising the need for data exclusions.
2.5  Data Analysis and Modelling
Descriptive analyses were used to examine responses to 
the tasks. For cTTO, this included inspecting the overall 
distribution of values and calculating means, medians, and 
standard deviations, both for each health state and grouped 
by level sum score (LSS; sum of the five dimension levels—
e.g., health state 13122 has an LSS of 1 + 3 + 1 + 2 + 2 = 
9). The proportion of respondents with logical inconsisten-
cies in their cTTO data—where a higher value was given 
to A than to B when B is at least as good as A across all 
dimensions—was also examined.
The data modelling strategy sought to take three key fea-
tures of the cTTO data into account. First, the minimum 
cTTO value is bounded at − 1 by design but respondents 
might have traded more time in full health had they been 
given the opportunity to do so, so responses were treated as 
left-censored at − 1. Second, each respondent undertook ten 
cTTO tasks so the modelling accounted for the possibility 
that observations from the same respondent would be more 
similar than those from other respondents. Third, it is com-
monly observed that the variance of TTO values increases 
as the severity of the health states increases (see [26, 31, 
32]). The extent to which this was the case in the Mexican 
data was examined by calculating the standard deviations 
of residuals (from a 20-parameter generalized least-squares 
(GLS) model) by health state, and modelling sought to 
account for this heteroscedasticity.
Four 20-parameter main effects cTTO models were esti-
mated. Model 1 was estimated by a GLS regression. The 
model accounted for the second feature of the cTTO data 
noted above, i.e., observations from the same respondent 
might be more similar than those from other respondents. 
Model 2 was estimated by a Tobit regression. The model 
addressed features 1 (i.e., cTTO data were censored at − 1) 
and 2 of the data. Model 3 is a heteroscedastic model with 
Bayesian estimation that accounted for features 2 and 3 (i.e., 
the variance of TTO values might increase as the severity 
of the health states increase) of the cTTO data. Model 4 
addressed all three features of the cTTO data using a het-
eroscedastic censored model with Bayesian estimation. The 
estimation was conducted using the Markov chain Monte 
Carlo simulation (MCMC) method with random walk 
Metropolis-Hastings algorithm [33]. To confirm the pres-
ence of feature 3 in the cTTO data, we checked whether the 
variance of residuals in the 20-parameter main effects GLS 
model was constant. Final model selection was informed by 
theoretical considerations relating to the characteristics of 
the cTTO data, logical ordering of the parameter estimates 
(i.e., larger decrements are expected for worse problems), 
significance of the parameters, and relevant information 
criteria (i.e., Bayesian information criterion (BIC), Akaike 
information criterion (AIC), Deviance information criterion 
(DIC)). As model 4 addressed all features of the cTTO data, 
we present its specification in detail below:
The latent variable cTTO∗
ij
 is censored at − 1. As a result, 
the observed variable cTTOij can only have values no less 
than the censored value.
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A 20-parameter model was estimated in modelling the 
observed cTTOij using Eq. (1).
where the 20 parameters for  reflect the decrement in util-
ity from full health as problems reported in each level and 
dimension of a health state. The utility for a health state is 
described by 20 dummies, i.e., MO2–MO5 (Mobility levels 
2–5), SC2–SC5 (Self-Care levels 2–5), UA2–UA5 (Usual 
Activities levels 2–5), PD2–PD5 (Pain/Discomfort levels 
2–5), and AD2–AD5 (Anxiety and Depression levels 2–5), 
with value equal to one if the category applies to the descrip-
tion of the health state and zero otherwise; ui is the respond-
ent level random intercept, ij is a heteroscedastic error term, 
subscript i refers to a respondent, subscript j accounts for 
each valuation task completed, iid refers to independent and 
identically distributed.
The heteroscedastic error term is specified by Eq. (2), 
which allows for an exponential relationship between the 
variance of the cTTO values and the severity of health states.
All models were run with and without applying the exclu-
sion criteria. Comparisons were made with the value sets of 
other selected countries.
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The mean interview duration—including background ques-
tions and task explanations as well as the cTTO and DCE 
tasks themselves—was 44.2 min (SD: 19.0 min; median: 
41.9 min). Of the sample, 38.0% self-reported being in 
health state 11111. Table 1 summarizes the background 
characteristics of the sample.
3.1  Data Characteristics
Using the feedback module, 2.1% of cTTO responses were 
flagged as problematic. These responses were excluded, 
leaving 9787 cTTO observations in the dataset for analy-
sis. No other data were excluded. No respondent gave the 
same value for all health states. The majority of respond-
ents (70.6%) had no logical inconsistencies within their 
cTTO data. Before excluding responses flagged via the 
feedback module, 67.3% of respondents had no logical 
inconsistencies.
The cTTO values and standard deviations increased with 
LSS. The mean observed cTTO values ranged from 0.96 
(for 11121) to − 0.66 (for 55555). Four health states out 
of the 86 that were valued directly—55555, 52455, 44553, 
and 43555—had a mean value of < 0. Of the 9787 cTTO 
valuations, 1925 (19.7%) were < 0. The proportions of val-
ues clustered at − 1, 0, and 1 were 6.9%, 1.3%, and 4.5%, 
respectively. Descriptive statistics of the values, by health 
state and by LSS, as well as the value distribution, are shown 
in Tables 1 and 2 of Section 3 in the ESM Appendix. The 
histogram of observed cTTO values is presented in Fig. 1 of 
Section 3 in the ESM Appendix.
3.2  Modelling Results
We checked whether our cTTO data show increased variance 
as the severity of the health states increases. This data fea-
ture was validated in two ways. First, in the test of whether 
the variance of residuals in the 20-parameter main effects 
GLS model was constant, the null hypothesis was rejected [p 
< 0.0001; χ2(1000) = 32429.5]. Second, it was shown graph-
ically that the standard deviation of residuals was greater for 
more severe health states (see Fig. 3 of Section 3 in the ESM 
Appendix). As the cTTO data presented all three features 
noted above, the chosen model should be able to address 
them all. Our preferred model is model 4, i.e., the Bayesian 
heteroscedasticity model with censoring at − 1.
Table  2 shows the cTTO results using the preferred 
model. Just under 4.5% of all TTO observations were left-
censored. Excluding observations flagged using the feedback 
module lowered the deviance information criterion (DIC) 
but did not substantially affect the model results—the only 
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Table 1  Sample background 
characteristics
All respondents (n = 1000) General popu-
lation (N = 
78,423,336)
N (%) N (%)
Age, years
 18–24 223 (22.3) 15,620,430 (19.9)
 25–34 261 (26.1) 18,849,051 (24.0)
 35–44 198 (19.8) 16,712,012 (21.3)
 45–54 130 (13.0) 12,005812 (15.3)
 55–64 100 (10.0) 7,657,834 (9.8)
 65–74 59 (5.9) 4,577,336 (5.8)
 75 and above 29 (2.9) 3,000,862 (3.8)
Gender
 Male 486 (48.6) 37,704,417 (48.1)
 Female 514 (51.4) 40,718,919 (51.9)
Region
 Region 1 100 (10.0) 7,931,675 (10.1)
 Region 2 192 (19.2) 15,093,816 (19.2)
 Region 3 126 (12.6) 9,682,184 (12.3)
 Region 4 237 (23.7) 18,697,285 (23.8)
 Region 5 118 (11.8) 9,124,117 (11.6)
 Region 6 145 (14.5) 11,178,743 (14.3)
 Region 7 82 (8.2) 6,715,516 (8.6)
Socioeconomic group
 A/B 107 (10.7) 7,920,757 (10.1)
 C+ 297 (29.7) 22,664,344 (28.9)
 C 151 (15.1) 12,312,464 (15.7)
 C− 142 (14.2) 11,292,960 (14.4)
 D+ 131 (13.1) 10,587,150 (13.5)
 D 111 (11.1) 8,783,414 (11.2)
 E 61 (6.1) 4,862,247 (6.2)
Self-rated mobility
 Level 1 770 (77.0) NA
 Level 2 148 (14.8)
 Level 3 59 (5.9)
 Level 4 16 (1.6)
 Level 5 7 (0.7)
Self-rated self-care
 Level 1 935 (93.50)
 Level 2 43 (4.30) NA
 Level 3 13 (1.30)
 Level 4 6 (0.60)
 Level 5 3 (0.30)
Self-rated usual activities
 Level 1 818 (81.80)
 Level 2 123 (12.30) NA
 Level 3 43 (4.30)
 Level 4 13 (1.30)
 Level 5 3 (0.30)
Self-rated pain/discomfort
 Level 1 555 (55.50)
 Level 2 299 (29.90) NA
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minor change was that without exclusions Anxiety/Depres-
sion 2 (AD2) had a marginally smaller coefficient than Pain/
Discomfort 2 (PD2), whereas after exclusions the AD2 
coefficient was marginally larger. All of the coefficients are 
logically ordered—that is, for any given dimension a higher 
level of problems has a larger coefficient (and therefore con-
fers more disutility) than a smaller level.
The MCMC sample size is 10,000. It is the result of 
12,500 MCMC iterations in total with the first 2500 itera-
tions discarded. The diagnostics of MCMC suggests good 
performance of the preferred model. The acceptance rate is 
reported as 43.91%. The average efficiency is 7.9%.
In the other models estimated (see Table 3 in Section 3 of 
the ESM Appendix), the coefficient for Mobility 2 (MO2) 
is negative but non-significant; all other coefficients are 
logically ordered and consistent with those of the preferred 
model. In all models, the largest utility decrement for a 
dimension-level is for PD5; the smallest is for MO2. There 
are large utility decrements in the moves from PD4 and AD4 
to PD5 and AD5, respectively.
3.3  Using the Preferred Value‑Set Model 
to Calculate EQ‑5D‑5L Health‑State Values
The EQ-5D-5L Mexican value set is based on cTTO data 
(with exclusions applied) modelled using the Bayesian het-
eroscedasticity model with censoring at − 1 (Table 2). To 
apply this model as an algorithm for obtaining EQ-5D-5L 
health-state values, the parameter estimates for each relevant 
dimension-level combination should be subtracted from 1 
(which represents full health). For example, the value for 
health state 12345 is 1–0–0.0476–0.0952–0.2283–0.3337 
= 0.2952.
The value set ranges from 0.984 for 21111 (mildest health 
state other than full health, describing slight problems in 
walking about and no problems on the other dimensions) 
to − 0.596 for 55555 (worst health state in the descriptive 
system). Based on the sizes of level 5 coefficients, the most 
important dimension is pain/discomfort, followed by anxi-
ety/depression, usual activities, mobility, and self-care.
3.4  Comparison with Value Sets of Other Countries
The results from the Mexican study can be compared to 
those of Uruguay [21], the first Latin American country to 
undertake an EQ-5D-5L valuation study; and the USA [25], 
Mexico’s neighbour to the north (Table 3). All three coun-
tries have based their value sets on cTTO data only. Mexico 
sits halfway between Uruguay and the USA in terms of the 
proportion of EQ-5D-5L health states with a modelled value 
of less than zero, though its minimum value of − 0.596 is the 
lowest of the three countries. Compared to the value sets of 
Uruguay and the USA, the Mexican value set places greater 
importance on anxiety/depression and usual activities, and 
less importance on mobility and self-care.
Another Latin American country—Peru—recently com-
pleted an EQ-5D-5L value-set study, albeit using a “Lite” 
protocol that is less reliant on the cTTO [34].
Table 1  (continued) All respondents (n = 1000) General popu-
lation (N = 
78,423,336)
N (%) N (%)
 Level 3 107 (10.70)
 Level 4 36 (3.60)
 Level 5 3 (0.30)
Self-rated anxiety/depression
 Level 1 661 (66.10)
 Level 2 242 (24.20) NA
 Level 3 77 (7.70)
 Level 4 19 (1.90)
 Level 5 1 (0.10)
Self-rated EQ-5D-5L health state
 Health state 11111 380 (38.00) NA
 Any other health state 620 (62.00)
 Self-rated EQ-VAS rating Mean = 83.2; Median = 90.0; SD = 
15.5
NA
Population projections based upon the Mexican Population Census 2010. For further details on Region and 
Socioeconomic group please refer to the ESM Appendix
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4  Discussion
The value set reported in this paper will enable evidence 
on QALYs, based on the preferences of Mexican people, to 
inform the HTA processes that Mexican healthcare authori-
ties use.
While both cTTO and DCE data were collected, follow-
ing the EuroQol EQ-5D-5L valuation protocol, the study 
team decided to base the value set on cTTO data. A number 
of other countries have also made this decision—including 
the USA and Uruguay, as noted earlier. Notably, the new 
EQ-5D-5L value set for the UK, recently announced by 
NICE and the EuroQol Group, will be based only on cTTO 
data as well [28]. Given the importance of this work for HTA 
in Mexico, and the greater acceptance of cTTO as a basis for 
the value sets to be used in HTA, this was deemed the pre-
ferred option a priori. The possibility of a hybrid model—
where both DCE and cTTO data are modelled together—was 
considered but rejected, given the lack of consensus regard-
ing hybrid models.
It is important to note the patterns in utility decrements 
associated with movements between levels on each of the 
dimensions in the cTTO model. The largest differences 
in coefficients are evident between levels 5 and 4 (on four 
of the dimensions), and these differences are particularly 
marked for pain/discomfort and anxiety/depression. For 
example, the difference between PD5 and PD4 is 0.2296. 
These characteristics of the value set will exert an influence 
on the estimation of QALY gains—for example, suggesting 
that a one-level improvement from extreme pain/discom-
fort will yield more QALY gains than a one-level improve-
ment from moderate pain/discomfort, ceteris paribus. The 
use of the value set to inform cost-effectiveness analysis 
will reflect these patterns of preferences. The availability 
of an EQ-5D-5L value set will facilitate local data collec-
tion using this instrument to inform future HTA decisions in 
Mexico. Exactly how the value set is to be used in HTA—for 
example, whether QALY estimates based on it should be 
accompanied by sensitivity analyses based on the standard 
errors—will require consideration and guidance from local 
decision makers.
Some limitations of the study should be mentioned. The 
design and methodology followed a well-established inter-
national valuation protocol, which involves basing health-
state utility values on the preferences of the general popu-
lation. This practice is informed by normative arguments 
(e.g., the argument that preferences ought to be elicited from 
behind a veil of ignorance rather than from individuals with 
vested interests) [35]. However, it has been criticized in the 
Table 2  cTTO model results: Heteroscedastic censored model with 
Bayesian estimation
Variance function for “heteroscedastic censored model with Bayes-






 ; MCSE refers to Monte-Carlo 
Standard Error
Dimension-level No exclusions With exclusion criteria 
applied
Coefficients MCSE Coefficients MCSE
Mobility 2 0.0168 0.000310 0.0160 0.000297
Mobility 3 0.0458 0.000427 0.0473 0.000403
Mobility 4 0.1727 0.000461 0.1786 0.000477
Mobility 5 0.2712 0.000479 0.2697 0.000426
Self-care 2 0.0489 0.000294 0.0476 0.000284
Self-care 3 0.0829 0.000473 0.0819 0.000475
Self-care 4 0.1691 0.000493 0.1697 0.000545
Self-care 5 0.2598 0.000486 0.2589 0.000487
Usual activities 2 0.0549 0.000283 0.0553 0.000288
Usual activities 3 0.0944 0.000479 0.0952 0.000393
Usual activities 4 0.1795 0.000409 0.1798 0.000447
Usual activities 5 0.2713 0.000528 0.2758 0.000507
Pain/discomfort 2 0.0549 0.000235 0.0531 0.000226
Pain/discomfort 3 0.0813 0.000462 0.0808 0.000429
Pain/discomfort 4 0.2288 0.000451 0.2283 0.000421
Pain/discomfort 5 0.4578 0.000446 0.4579 0.000442
Anxiety/depres-
sion 2
0.0548 0.000262 0.0551 0.000259
Anxiety/depres-
sion 3
0.0833 0.000468 0.0824 0.000507
Anxiety/depres-
sion 4
0.1647 0.000506 0.1611 0.000481
Anxiety/depres-
sion 5
0.3338 0.000424 0.3337 0.000412
α0 − 1.6296 0.000560 − 1.6435 0.000545








Table 3  Comparison of Mexican, Uruguayan, and USA value-set 
characteristics
a TTO model—Bayesian heteroscedasticity model censored at − 1
b Based on the relative sizes of the level 5 coefficients
c Pain/discomfort (PD); anxiety/depression (AD); usual activities 
(UA); mobility (MO); self-care (SC)
Mexicoa Uruguay USA
Proportion of 
worse than dead 
health states
9.1% 0.9% 20.0%
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literature and there have been calls to use preferences from 
patients (either instead of or in addition to public prefer-
ences) [36, 37] as patients are likely to be better informed 
than the public about what it is like to live in states of 
impaired health.
Preference data were collected using two techniques—
cTTO and DCE—but the value set is based only on TTO 
data. While there are reasonable grounds for this decision 
(described above), it means that the DCE data collected will 
play no role in informing HTA decision making in Mexico. 
Further, the TTO technique is itself subject to limitations 
[38] (though it is worth noting that this is true of all stated 
preference methods). The cTTO and DCE data showed 
markedly different preference patterns (see Section 2 of the 
ESM Appendix for an overview of the DCE results). Our 
existing analyses have not been able to fully explain the 
reasons for these differences. Qualitative methods—such as 
think-aloud interviews—may help to explore this issue, but 
these were not included as part of the current study.
5  Conclusions
The EQ-5D-5L value set reported in this study is the first 
value set produced for any health-related quality of life 
instrument in Mexico. The provision of a value set, which 
reflects the distinctive preferences of the adult Mexican gen-
eral public, will facilitate and support use of EQ-5D-5L in 
multicenter clinical trials and quality-of-life studies. This 
will in turn improve the evidence used in HTA to define 
technologies that might be financed by public healthcare 
institutions.
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